During an investor call, UnitedHealth Group executives talk about the steps it has taken to increase transparency, use technology to reshape its healthcare delivery and address how it adapting to financial pressures across its Medicare, Medicaid, and Affordable Care Act businesses.
In a Q&A, Jeffrey Hogan, managing director and co-founder of Judi Group, talks about the importance of identifying hidden costs and contract conflicts of healthcare vendors.
Legislation reforms pharmacy benefit managers by mandating price transparency, eliminating certain compensation models, and providing CMS funding to enforce contract terms.
Lawmakers from both parties grill insurance companies over claims denials, prior authorization delays, and vertical integration.
Judi Group brings together top benefits specialists, ERISA attorneys, actuarial analysts, and technologists to assess risk and protect fiduciary integrity across vendors and solutions.
Dynavax's Z-1018 shingles vaccine in a phase 1/2 trial showed comparable effectiveness to Shingrix with fewer injection site reactions in adults aged 50 to 69.
Medicare’s recently released drug pricing models GLOBE and GUARD use international price benchmarks to generate government rebates but experts say they are unlikely to reduce costs for patients.
Duravyu demonstrated vision improvement in phase 2 trials in patients with diabetic macular edema. Phase 3 trials are enrolling patients now.
Elevated levels of lipoprotein(a) is a genetic disease that causes cardiovascular disease. Steven Nissen, M.D., addresses why it’s important to find treatments for this genetic risk factor.
Beginning this month, PBMs in California must prioritize health plan interests over their own, and CVS Caremark’s CalPERS contract includes $250 million in performance guarantees.
Existing medications for narcolepsy aim for symptom control. But therapies in development are targeting the specific mechanism of the disease and the brain’s natural sleep-wake cycle.
Five experimental drugs show promise in significantly lowering lipoprotein(a). The furthest along is pelacarsen, with phase 3 results expected in the first half of this year, and regulatory filings in the second half of this year.
Lytenava, an ophthalmic bevacizumab formulation to treat patients with wet age-related macular degeneration, received yet another FDA complete response letter. The agency is asking for confirmatory efficacy data beyond existing NORSE trial results.
University of Florida researchers found immune systems destroy single beta cells before attacking larger pancreatic islets, explaining Type 1 diabetes progression and why younger patients lose cells more aggressively.
To gain approvals, biosimilar manufacturers could do faster, less expensive analytical studies of their products' composition.
The results of an American Society of Health-System Pharmacists survey shed some light on what is on the minds of pharmacy leaders at health systems.
Ophthalmologists and oncologists created a new ocular adverse event grading scale for oncology trials that addresses ambiguities and provides clear dose modification recommendations.
The biosimilar market experienced 16 new approvals by early December 2025, marking significant expansion and introducing previously unavailable biosimilar drug classes to patients.
Medicare's first negotiated drug prices, effective January 2026, provide modest discounts, with limited savings for most beneficiaries and some unintended consequences.
A new Tufts study found that Medicare price negotiations on biologics with imminent biosimilars could lead to near-term savings, but greater savings are likely from biosimilar competition.
Melanoma survival rates have doubled since 2009. New treatments, including oncolytic viruses, fecal transplants, and engineered antibodies, have shown promising results in clinical trials.
Tranexamic acid given during noncardiac surgery reduced blood transfusions by 2.4% without increasing blood clots, potentially saving millions of transfusion units annually nationwide.
A phase 3 trial showed that Jaypirca improved progression-free survival in newly diagnosed patients with chronic lymphocytic leukemia and small lymphocytic lymphoma compared with standard chemotherapy/rituximab regimen.
Early results from the LINKER-MM4 trial show high response rates for linvoseltamab, offering new hope for newly diagnosed patients.
Early results from the LINKER-MM4 trial reveal promising response rates for linvoseltamab in newly diagnosed multiple myeloma patients, with manageable side effects.
Jaypirca demonstrated non-inferior response rates compared with Imbruvica in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, with fewer cardiovascular events and dose reductions.
Venclexta-azacitidine combination offered better responses with less hospitalization and lower symptom burden compared with standard chemotherapy in patients with acute myeloid leukemia who are fit for transplant.
Adults with sickle cell disease face longer emergency department wait times for pain treatment than children, with women experiencing more delays than men.
A budget model analysis finds that biosimilars for Prolia and Xgeva could provide cost savings for health plans.
